Blogs about: Dendreon
Featured Blog
The IMPACT trial results: Tuesday April 27, 2009
OK … so here are the results we have all been waiting for for the past few weeks — the data from the IMPACT trial comparing the survival of patients treated with three doses of sipuleucel-… more →
THE "NEW" PROSTATE CANCER INFOLINK
Molecular Insight Pharmaceuticals: In the Prostate Cancer Spotlight
Michael Becker wrote 1 month ago: Prostate cancer is the most common type of cancer found in American men, other than skin cancer. In … more →
PROSTATE FUTURE: New drug will be ready for baby boomers
Jim Tucker wrote 1 month ago: JUNE 11: SEEKING ALPHA.COM: A groundbreaking new treatment for prostate cancer, Provenge, will likel … more →
Five key principles for life science companies to not only survive – but thrive – in the current environment
Michael Becker wrote 1 month ago: On May 7, 2009, MD Becker Partners LLC hosted its inaugural life sciences roundtable titled “Success … more →
Biotech Stocks and the ASCO-effect
Michael Becker wrote 1 month ago: Investors are hoping that the spark that could reignite investor enthusiasm for biotech stocks is ta … more →
Industry Report: Biotech -- drug research not for the faint at heart
bryancorliss wrote 1 month ago: First published March 23, 2008 Biotech is a high-risk, high-reward business. Years of very expensive … more →
Some feel good data
Tan A K wrote 2 months ago: As the month draws to a close, April is on its way to seeing the best monthly gain since 1991 after … more →
Sears (SHLD) Offers $6.75 For Restoration Hardware (RSTO) In Bad ...
raskeocu wrote 2 months ago: Rising Stars Through Oval [RSTO] Series – By Elite Racing Leagues … more →
The IMPACT trial results: Tuesday April 27, 2009
— 2 comments
Sitemaster wrote 2 months ago: OK … so here are the results we have all been waiting for for the past few weeks — the d … more →
Market Recap: Survivability
Joshua M Brown wrote 2 months ago: The Reformed Broker, AKA Prince Adam, here with today’s Market Recap… Once again, t … more →
Dendreon releases positive study results
Tan A K wrote 2 months ago: This just coming in from CNBC: Provenge, the prostate cancer treatment by Dendreon, extended the liv … more →
Provenge data results ... for those who can't get to the AUA meeting
Sitemaster wrote 2 months ago: Dendreon has previously announced that the results of the IMPACT trial will be presented at the annu … more →
Today's Top Three in Pharma 041609
Steve Woodruff wrote 3 months ago: GSK and Pfizer join forces to create a new company focused on HIV. I really like the idea here … more →
Can SmallCap Prostate Cancer Firms Borrow Some of Dendreon’s Spotlight?
AllenCaron wrote 3 months ago: Forty-eight hours ago, the market cap of Dendreon, (Nasdaq:DNDN) www.dendreon.com, fell squarely wit … more →
FT says that another Provenge trial may still be needed
— 3 comments
Sitemaster wrote 3 months ago: OK folks … please don’t shoot the messenger … I do not agree with the suggestions … more →
Bernanke sees 'tentative signs' of improvement
allen wrote 3 months ago: Hedge Funds : US Town Claws Back £17m Of Madoff Assets http://www.hedgeco.net/n/10338 Newsweek: Who … more →
Dendreon stock surges on "clear hit" of prostate cancer vaccine.
darkhorsetrader wrote 3 months ago: http://blogs.wsj.com/health/2009/04/14/dendreons-shares-come-back-to-life-on-prostate-cancer-data/?m … more →
The full Provenge saga
— 2 comments
Sitemaster wrote 3 months ago: For those who have come to the world of prostate cancer in the past 2 years or so, we recommend that … more →
Today's Top Three in Pharma 032509
Steve Woodruff wrote 3 months ago: Just what we need – another takeover rumor! Is GSK interested in Allergan? Or, perhaps, is All … more →
Where Might Genentech Investors Redeploy $47 Billion?
Michael Becker wrote 4 months ago: Following a spate of high profile clinical setbacks and regulatory delays that sent the sector into … more →
Have your say. Start a blog.
See our free features →
An 
Joint
